Skip to main content
SpringerLink
Log in

Three Novel NF1 Gene Mutations in a Cohort of Bulgarian Neurofibromatoses Patients

  • Medical Genetics
  • Published:
Russian Journal of Genetics Aims and scope Submit manuscript

Abstract

Neurofibromatosis (NF) is a clinically heterogeneous autosomal dominant disorder. Three distinct forms have been identified: neurofibromatosis type 1 (NF1), type 2 (NF2) and schwannomatosis. In the present study, we report clinical and genetic findings in the NF1 and NF2 genes in a cohort of 27 Bulgarian patients, with 18 cases (67%) genetically verified. Both NF1 and NF2 genes were screened by Sanger sequencing on DNA samples. The Sanger negative samples were screened by Multiplex Ligation-dependent Probe Amplification (MLPA) for deletions and duplications. The results from genetic testing revealed three novel mutations and fifteen previously reported ones (13 in the NF1 gene and 2 in the NF2 gene). The novel variants in the NF1 gene are a splice site mutation c.4725-1G>A, a small deletion of five bases c.823delATCTT, p.Leu275ValfsTer14, and a single base duplication c.6547dupC, p.Arg2183ProfsTer11. The novel splice site mutation is manifested by multiple “café au lait” macules and neurofibromas. Both novel out of frame mutations were found in patients with multiple “café au lait” spots and focal epilepsy. A segmental neurofibromatosis (SNF1) is restricted to one or more body segments. Here we present a case with SNF1 caused by a somatic deletion of exons 1 to 12 of the NF1 gene which is manifested by multiple neurofibromas in the right hand. Two nonsense mutations are found in the NF2 gene. Our study adds three novel mutations to the NF1 mutation spectra and contributes to the clinical-genetic NF1-characterization. Here we report strikingly different phenotypic spectra caused by the same mutation in a single family. Our findings contribute to the genotype- phenotype correlations which are difficult to establish, due to the extremely complex NF phenotype being a combination of clinical features.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Huson, S.M., The neurofibromatoses: classification, clinical features and genetic counselling, Monographs in Human Genetics, Schmid, M., Ed., vol. 16: Neurofibromatoses, Kaufmann, D., Ed., Karger: Basel, 2008, pp. 1–20.

    Google Scholar 

  2. Yohay, K.H., The genetic and molecular pathogenesis of NF1 and NF2, Semin. Pediatr. Neurol., 2006, vol. 13, no. 1, pp. 21–26.

    Article  PubMed  Google Scholar 

  3. Morais, P., Ferreira, O., Bettencourt, H., and Azevedo, F., Segmental neurofibromatosis: a rare variant of a common genodermatosis, Acta Dermatovenerol. Alp. Panonica Adriat., 2010, vol. 19, pp. 27–29.

    CAS  Google Scholar 

  4. Sobjanek, M., Dobosz-Kawałko, M., Michajłowski, I., Pęksa, R., et al., Segmental neurofibromatosis, Postepy Dermatol. Alergol., 2014, vol. 31, no. 6, pp. 410–412.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Bessonova, L.A., El’chinova, G.I., and Zinchenko, R.A., Population genetics of hereditary diseases in the child population of the Republic of Bashkortostan, Chuvashia, and Udmurtia, Russ. J. Genet., 2012, vol. 48, no. 5, pp. 644–654.

    Article  CAS  Google Scholar 

  6. Neurofibromatosis: conference statement, National Institutes of Health Consensus Development Conference, Arch. Neurol. Chicago., 1988, vol. 45, pp. 575–578.

  7. Ferner, R.E., Huson, S.M., Thomas, N., et al., Guidelines for the diagnosis and management of individuals with neurofibromatosis 1, J. Med. Genet., 2007, vol. 44, no. 2, pp. 81–88.

    Article  CAS  PubMed  Google Scholar 

  8. García-Romero, M.T., Parkin, P., and Lara-Corrales, I., Mosaic neurofibromatosis type 1: a systematic review, Pediatr. Dermatol., 2016, vol. 33, no. 1, pp. 9–17.

    Article  PubMed  Google Scholar 

  9. Ruggieri, M., The different forms of neurofibromatosis, Childs Nerv. Syst., 1999, vol. 15, nos. 6—7, pp. 295–308.

    Article  CAS  PubMed  Google Scholar 

  10. Ruggieri, M. and Huson, S.M., The clinical and diagnostic implications of mosaicism in the neurofibromatoses, Neurology, 2001, vol. 56, pp. 1433–1443.

    Article  CAS  PubMed  Google Scholar 

  11. Ruggieri, M., Pavone, P., Polizzi, A., et al., Ophthalmological manifestations in segmental neurofibromatosis type 1, Br. J. Ophthalmol., 2004, vol. 88, pp. 1429–1433.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Ruggieri, M. and Praticò, A.D., Mosaic neurocutaneous disorders and their causes, Semin. Pediatr. Neurol., 2015, vol. 22, no. 4, pp. 207–233.

    Article  PubMed  Google Scholar 

  13. Hager, C.M., Cohen, P.R., and Tschen, J.A., Segmental neurofibromatosis: case reports and review, Am. J. Acad. Dermatol., 1997, vol. 37, pp. 864–869.

    Article  CAS  Google Scholar 

  14. Ilyas, A.M., Nourissat, G., and Jupiter, J.B., Segmental neurofibromatosis of the hand and upper extremity: a case report, J. Hand. Surg. Am., 2007, vol. 32, no. 10, pp. 1538–1542.

    Article  PubMed  Google Scholar 

  15. Kazubskaia, T.P., Kozlova, V.M., Musatov, V.K., et al., Identification of the hereditary variants of skin melanoma, Russ. J. Genet., 2004, vol. 40, no. 1, pp. 88–96.

    CAS  Google Scholar 

  16. Shen, M.H., Harper, P.S., and Upadhyaya, M., Molecular genetics of neurofibromatosis type 1 (NF1), J. Med. Genet., 1996, vol. 33, pp. 2–17.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Fahsold, R., Hoffmeyer, S., Mischung, C., et al., Minor lesion mutational spectrum of the entire NF1 gene does not explain its high mutability but points to a functional domain upstream of the GAP-related domain, Am. J. Hum. Genet., 2000, vol. 66, no. 3, pp. 790–818.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Evans, D.G., Neurofibromatosis type 2 (NF2): a clinical and molecular review, Orphanet J. Rare Dis., 2009, vol. 19, pp. 4–16.

    Google Scholar 

  19. Ruggieri, M., Praticò, A.D., and Evans, D.G., Diagnosis, management, and new therapeutic options in childhood neurofibromatosis type 2 and related forms, Semin. Pediatr. Neurol., 2015, vol. 22, no. 4, pp. 240–258.

    Article  PubMed  Google Scholar 

  20. Lloyd, S.K. and Evans, D.G., Neurofibromatosis type 2 service delivery in England, Neurochirurgie, 2016. doi 10.1016/j.neuchi.2015.10.006

    Google Scholar 

  21. Slattery, W.H., Neurofibromatosis type 2, Otolaryngol. Clin. North Am., 2015, vol. 48, no. 3, pp. 443–460.

    Article  PubMed  Google Scholar 

  22. Baser, M.E., Kuramoto, L., Joe, H., et al., Genotype—phenotype correlations for nervous system tumors in neurofibromatosis 2: a population-based study, Am. J. Hum. Genet., 2004, vol. 75, pp. 231–239.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Baser, M.E., Kuramoto, L., Woods, R., et al., The location of constitutional neurofibromatosis 2 (NF2) splice site mutations is associated with the severity of NF2, J. Med. Genet., 2005, vol. 42, no. 7, pp. 540–546.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Dubatolova, T.D., Kopyl, S.A., Bulgakovam, N.A., et al., Effect of mutations in Drosophila melanogaster tumor suppressor Merlin on proliferation and differentiation of wing cells, Russ. J. Genet., 2010, vol. 46, no. 2, pp. 187–193.

    Article  CAS  Google Scholar 

  25. Dubatolova, T.D., Dorogova, N.V., Omel’ianchuk, L.V., and Chang, L.S., Duration of the cell cycle phases in mutants for the tumor suppressor Merlin in Drosophila melanogaster, Russ. J. Genet., 2011, vol. 47, no. 4, pp. 460–465.

    Article  CAS  Google Scholar 

  26. Iudina, O.S., Gusachenko, A.M., Akhmamet’eva, E.M., and Omel’ianchuk, L.V., Chromosome nondisjunction in Drosophila strains mutant for tumor suppressor Merlin, Russ. J. Genet., 2008, vol. 44, no. 3, pp. 414–416.

    CAS  Google Scholar 

  27. Den Dunnen, J.T., Dalgleish, R., Maglott, D.R., et al., HGVS recommendations for the description of sequence variants: Human Genome Variation Society (HGVS), the Human Variome Project (HVP) and the Human Genome Organisation (HUGO), Hum. Mutat., 2016, update. doi 10.1002/humu.22981

    Google Scholar 

  28. Ferner, R. and Gutman, D., Handbook of Clinical Neurology Peripheral Nerve Disorders, Said, G. and Krarup, C., Eds., in Neurofibromatosis Type 1 (NF1): Diagnosis and Management, Elsevier, 2013, 3rd ed., pp. 939–955.

    Google Scholar 

  29. Deo, M., Huang, J.L., Fuchs, H., et al., Differential effects of neurofibromin gene dosage on melanocyte development, J. Invest. Dermatol., 2013, vol. 133, no. 1, pp. 49–58.

    Article  CAS  PubMed  Google Scholar 

  30. Abramowicz, A. and Gos, M., Neurofibromin in neurofibromatosis type 1—mutations in NF1 gene as a cause of disease, Dev. Period. Med., 2014, vol. 18, no. 3, pp. 297–306.

    PubMed  Google Scholar 

  31. Castle, B., Baser, M. E., Huson, S. M., et al., Evaluation of genotype—phenotype correlations in neurofibromatosis type 1, J. Med. Genet., 2003, vol. 40. e109

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Sabbagh, A., Pasmant, E., Imbard, A., et al., NF1 molecular characterization and neurofibromatosis type I genotype—phenotype correlation: the French experience, Hum. Mutat., 2013, vol. 34, no. 11, pp. 1510–1518.

    Article  CAS  PubMed  Google Scholar 

  33. Kweh, F., Zheng, M., Kurenova, E., et al., Neurofibromin physically interacts with the N-terminal domain of focal adhesion kinase, Mol. Carcinog., 2009, vol. 48, no. 11, pp. 1005–1017.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Williams, V.C., Lucas, J., Babcock, M.A., et al., Neurofibromatosis type 1 revisited, Pediatrics, 2009, vol. 123, no. 1, pp. 124–133.

    Article  PubMed  Google Scholar 

  35. Trovó-Marqui, A.B. and Tajara, E.H., Neurofibromin: a general outlook, Clin. Genet., 2006, vol. 70, no. 1, pp. 1–13.

    Article  PubMed  Google Scholar 

  36. Gammel, J.A., Localized neurofibromatosis, Arch. Dermatol. Syph., 1931, vol. 24, pp. 712–715.

    Article  Google Scholar 

  37. Crowe, F.W., Schull, W.J., and Neel, J.V., Clinical, Pathological, and Genetic Study of Multiple Neurofibromatosis, Springfield (IL): Charles C Thomas, 1956.

    Google Scholar 

  38. Miller, R.M. and Sparkes, R.S., Segmental neurofibromatosis, Arch. Dermatol., 1977, vol. 123, pp. 837–838.

    Article  Google Scholar 

  39. Riccardi, V.M., Neurofibromatosis: clinical heterogeneity, Curr. Probl. Cancer, 1982, vol. 7, pp. 1–34.

    Article  CAS  PubMed  Google Scholar 

  40. Roth, R.R., Martines, R., and James, W.D., Segmental neurofibromatosis, Arch. Dermatol., 1987, vol. 123, pp. 917–920.

    Article  CAS  PubMed  Google Scholar 

  41. Gorlin, R., Cohen, M.M., Jr., and Levine, M., The neurofibromatoses (NfI Recklinghausen type, NfII acoustic type, other types), in Syndromes of the Head and Neck, Gorlin, R., Cohen, M.M., Jr., and Levine, M., Eds., Oxford: Oxford University Press, 1992, pp. 392–399.

    Google Scholar 

  42. Garcia-Linares, C., Fernández-Rodríguez, J., Terribas, E., et al., Dissecting loss of heterozygosity (LOH) in neurofibromatosis type 1 associated neurofibromas: importance of copy neutral LOH, Hum. Mutat., 2011, vol. 32, no. 1, pp. 78–90.

    Article  CAS  PubMed  Google Scholar 

  43. Laczmańska, I., Szczepaniak, M., Jakubiak, A., and Stembalska, A., Exonic deletions in the NF1 gene in patients with neurofibromatosis type 1 from the lower Silesian region of Poland, Adv. Clin. Exp. Med., 2014, vol. 23, no. 4, pp. 517–521.

    Article  PubMed  Google Scholar 

  44. Evans, D.G., Trueman, L., Wallace, A., et al., Genotype/phenotype correlations in type 2 neurofibromatosis (NF2): evidence for more severe disease associated with truncating mutations, J. Med. Genet., 1998, vol. 35, no. 6, pp. 450–455.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Chemistry and Biochemistry, Medical University Sofia, Sofia, 1431, Bulgaria

    M. Glushkova, A. Todorova & V. Mitev

  2. Genetic Medico-Diagnostic Laboratory Genica, Sofia, 1612, Bulgaria

    M. Glushkova, I. Yordanova, T. Todorov & A. Todorova

  3. Clinic of Child Neurology, University Hospital “Sv. Naum,” Medical University Sofia, Sofia, 1113, Bulgaria

    V. Bojinova & M. Koleva

  4. Epilepsy Center, Department of Neurosurgery, University Hospital “St. Ivan Rilski,”, Sofia, 1431, Bulgaria

    P. Dimova

  5. Department of Neurology, Medical University Sofia, Sofia, 1431, Bulgaria

    I. Tournev

  6. Department of Cognitive Science and Psychology, New Bulgarian University, Sofia, 1618, Bulgaria

    I. Tournev

  7. Department of Pediatric Diseases and Medical Genetics, Medical University Varna, Varna, 9002, Bulgaria

    L. Angelova

Authors
  1. M. Glushkova
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. I. Yordanova
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T. Todorov
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. V. Bojinova
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. Koleva
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. P. Dimova
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. I. Tournev
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. L. Angelova
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. A. Todorova
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. V. Mitev
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Glushkova.

Additional information

The article is published in the original.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Glushkova, M., Yordanova, I., Todorov, T. et al. Three Novel NF1 Gene Mutations in a Cohort of Bulgarian Neurofibromatoses Patients. Russ J Genet 54, 110–116 (2018). https://doi.org/10.1134/S1022795418010040

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1134/S1022795418010040

Keywords

Search

Navigation